-
公开(公告)号：KR1020000058218A
公开(公告)日：2000-09-25
申请号：KR1020000028976
申请日：2000-05-29
Applicant: 한국과학기술연구원
IPC: A61K31/35
Abstract: PURPOSE: A composition containing naringin or naringenin for inhibition of the platelet coagulation is provided, which prevents coagulation of platelets caused by exposed collagen when blood vessel endothelial cells is damaged; so which can prevents and cures formation of atheroma, or thrombosis; and which can be used in a medicine and food. CONSTITUTION: A naringin or naringenin is extracted from oranges(a grapefruit, a citron, a lemon, a orange, etc) or manufactured from well-known synthetic process. A pharmaceutical composition as an inhibitor to platelet coagulation comprises of naringin or naringenin as an effective ingredient and pharmaceutically acceptable carriers, which can also contains diluents, disintegrators, sweeteners, lubricants, perfume; and which can be made in the form of tablets, capsules, powders, suspensions, emulsions, syrup, solution or parenteral preparations. A dosage of the composition for inhibition of the platelet coagulation containing naringin or naringenin is 0.5-100mg/kg, desirably 2-10mg/kg. The naringin or naringenin can be added in food or beverages with same purposes.
Abstract translation: 目的：提供含有柚皮苷或柚皮素抑制血小板凝集的组合物，可防止血管内皮细胞损伤时由胶原蛋白引起的血小板凝结; 因此可以预防和治愈动脉粥样化的形成或血栓形成; 并可用于医药和食品。 构成：从橘子（葡萄柚，柚子，柠檬，橙子等）中提取柚皮苷或柚皮素，或由熟知的合成过程制成。 作为血小板凝血抑制剂的药物组合物包含柚皮苷或柚皮苷作为有效成分和药学上可接受的载体，其还可以含有稀释剂，崩解剂，甜味剂，润滑剂，香料; 并且其可以以片剂，胶囊，粉末，悬浮液，乳剂，糖浆，溶液或肠胃外制剂的形式制成。 用于抑制含有柚皮苷或柚皮苷的血小板凝血的组合物的剂量为0.5-100mg / kg，优选为2-10mg / kg。 柚皮苷或柚皮素可加入具有相同目的的食品或饮料中。
-
公开(公告)号：KR1020000000753A
公开(公告)日：2000-01-15
申请号：KR1019980020562
申请日：1998-06-03
Applicant: 한국과학기술연구원
IPC: A61K31/35 , A61K31/715
CPC classification number: A23L33/10 , A23L2/38 , A23V2002/00 , A23V2200/30 , A61K31/352 , A61K31/704
Abstract: PURPOSE: A composition is provided to help to improve the blood flow by preventing a platelet cohesion and a formation of a thrombus at the same time. CONSTITUTION: The hesperidins or the hesperetin is effective to prevent and treat the sclerosis of the arteries by the platelet cohesion, and to improve of the blood flow by preventing the platelet cohesion generated by collagen. The composition for the platelet cohesion prevention is able to prescribe as a non-oral administration or to prescribe as an oral administration, and to prescribe the hesperidins or the hesperetin 0.5 mg or 100 mg for 1 kg per a day.
Abstract translation: 目的：提供一种组合物，以帮助通过同时预防血小板凝聚和形成血栓来改善血流量。 构成：橙皮苷或橙皮素通过血小板凝聚力预防和治疗动脉硬化有效，并且通过防止胶原产生的血小板凝聚力来改善血流量。 用于血小板凝聚防止的组合物可以作为非口服给药或作为口服给药开处方，并且将每天1kg的橙皮苷或橙皮素0.5mg或100mg开处方。
-
-
Patent Agency Ranking
公开(公告)号：KR1020000058219A
公开(公告)日：2000-09-25
申请号：KR1020000028977
申请日：2000-05-29
Applicant: 한국과학기술연구원
IPC: A61K31/35
Abstract: PURPOSE: A composition containing hesperidin or hesperetin for inhibition of the platelet coagulation is provided, which prevents coagulation of platelets caused by exposed collagen when blood vessel endothelial cells is damaged; so which can prevents and cures formation of atheroma, or thrombosis; and which can be used in a medicine and food. CONSTITUTION: A hesperidin or hesperetin is extracted from oranges(a grapefruit, a citron, a lemon, a orange, etc) or manufactured from well-known synthetic process. A pharmaceutical composition as an inhibitor to platelet coagulation comprises of naringin or naringenin as an effective ingredient and pharmaceutically acceptable carriers, which can also contains diluents, disintegrators, sweeteners, lubricants, perfume; and which can be made in the form of tablets, capsules, powders, suspensions, emulsions, syrup, solution or parenteral preparations. A dosage of the composition for inhibition of the platelet coagulation containing naringin or naringenin is 0.5-100mg/kg, desirably 2-10mg/kg. The hesperidin or hesperetin can be added in food or beverages with same purposes.
Abstract translation: 目的：提供含有用于抑制血小板凝血的橙皮苷或橙皮素的组合物，其防止血管内皮细胞损伤时由胶原蛋白引起的血小板凝结; 因此可以预防和治愈动脉粥样化的形成或血栓形成; 并可用于医药和食品。 构成：橙子（葡萄柚，香橼，柠檬，橙子等）中提取橙皮苷或橙皮素，或由熟知的合成方法制成。 作为血小板凝血抑制剂的药物组合物包含柚皮苷或柚皮苷作为有效成分和药学上可接受的载体，其还可以含有稀释剂，崩解剂，甜味剂，润滑剂，香料; 并且其可以以片剂，胶囊，粉末，悬浮液，乳剂，糖浆，溶液或肠胃外制剂的形式制成。 用于抑制含有柚皮苷或柚皮苷的血小板凝血的组合物的剂量为0.5-100mg / kg，优选为2-10mg / kg。 橙皮苷或橙皮素可以添加到具有相同目的的食品或饮料中。
-
-
-
-
公开(公告)号：KR1020000000752A
公开(公告)日：2000-01-15
申请号：KR1019980020561
申请日：1998-06-03
Applicant: 한국과학기술연구원
IPC: A61K31/35 , A61K31/715
CPC classification number: A23L33/10 , A23L2/38 , A23V2002/00 , A23V2200/30 , A61K31/352 , A61K31/704
Abstract: PURPOSE: A composition is provided to help to improve the blood flow by preventing a platelet cohesion and a formation of a thrombus at the same time. CONSTITUTION: The naringin or the naringenin is effective to prevent and treat the sclerosis of the arteries by the platelet cohesion, and to improve the blood flow by preventing the platelet cohesion generated by collagen. The medical composition is a preventing agent of the platelet cohesion and comprises by mixing the naringin or the naringenin as an efficient component and a carrier permitted for a pharmacology. And a diluent, a disintegrator, a sweetening agent, a lubricant, and a cordial are included.
Abstract translation: 目的：提供一种组合物，以帮助通过同时预防血小板凝聚和形成血栓来改善血流量。 构成：柚皮苷或柚皮苷有效预防和治疗血小板聚集的动脉硬化，并通过防止胶原蛋白产生的血小板凝聚力来改善血流量。 该药物组合物是血小板聚集性的预防剂，包括将柚皮苷或柚皮苷作为有效成分和允许药理学的载体混合。 并且包括稀释剂，崩解剂，甜味剂，润滑剂和亲和物。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.02 seconds)
